TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34574458
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (CHM) - Astragali Radix
Study: 34574458
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine (CHM) - Salviae Miltiorrhizae Radix et Rhizoma
Study: 32429737
Drug: Tart Cherry
Normalized name: Tart Cherry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tart Cherry Juice (240 mL, twice daily for 12 weeks)
Study: 32429737
Drug: Control (isocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (isocaloric placebo drink, twice daily for 12 weeks)
Study: 36575506
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL of a clear supplement containing 10 g of whey protein and 54 g of carbohydrates (WP+CHO)
Study: 36575506
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL of a clear supplement containing 12.5% maltodextrin (25 g) (CHO)
Study: 36064604
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of ABCB5+ mesenchymal stem cells (MSCs)
Study: 34128498
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (plate fixation with a precontoured distal clavicular plate or a 'hook' plate within 28 days from injury)
Study: 34128498
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (standard shoulder sling, followed by pendulum or gentle range of motion shoulder exercises)
Study: 32920032
Drug: water soluble
Normalized name: WATER SOLUBLE BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: water soluble gel
Study: 34195206
Drug: Short-term low-dose
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term low-dose lithium therapy for three consecutive days
Study: 34195206
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for three consecutive days
Study: 34649083
Drug: Control 'treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control 'treatment as usual' (TAU)
Study: 35678020
Drug: Argatroban plus
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban plus dual antiplatelet therapy (DAPT)
Study: 33337738
Drug: Gadoterate administration
Normalized name: GADOTERATE
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadoterate administration after premedication with corticosteroid and diphenhydramine
Study: 33337738
Drug: Gadoterate administration
Normalized name: GADOTERATE
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadoterate administration with corticosteroid premedication
Study: 33337738
Drug: Gadoterate administration
Normalized name: GADOTERATE
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadoterate administration without corticosteroid premedication
Study: 32925623
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral E2 with or without vaginal progesterone
Study: 38800802
Drug: Sintilimab plus
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab plus chemotherapy
Study: 34098728
Drug: Abdominal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal treatment
Study: 34098728
Drug: Combined with
Normalized name: Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined with oral use of tamsulosin at 0.4 mg daily
Study: 33683016
Drug: Drug being
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug being tested to prevent hypertensive complications
Study: 32819842
Drug: Follitropin delta
Normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin delta 10.0 µg
Study: 32819842
Drug: Follitropin delta
Normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin delta 10.3 µg
Study: 32819842
Drug: Follitropin delta
Normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin delta 9.7 µg
Study: 32819842
Drug: Follitropin delta
Normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin delta 9.3 µg
Study: 32819842
Drug: Follitropin delta
Normalized name: follitropin delta
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follitropin delta 9.5–10.4 µg
Study: 35246827
Drug: fosaprepitant 150
Normalized name: fosaprepitant 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fosaprepitant 150 mg
Study: 38697155
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of physician's choice
Study: 34020596
Drug: Conventional Fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Fluid Therapy (CFT)
Study: 32928560
Drug: Quercetin 75
Normalized name: vitamin A/vitamin C/vitamin D3/zinc/acetylcysteine/quercetin 750 mcg-150 mg-31.25 mcg-10 mg-300 mg-100 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 75 μg/ml (Q75)
Study: 32928560
Drug: Quercetin 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 150 μg/ml (Q150)
Study: 32928560
Drug: Quercetin 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 300 μg/ml (Q300)
Study: 32122219
Drug: Anakinra once
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra once daily (N=33)
Study: 32122219
Drug: Anakinra twice
Normalized name: anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anakinra twice daily (N=31)
Study: 32122219
Drug: Anakinra (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (both dosing regimens combined)
Study: 35470813
Drug: Stepped-care cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped-care cognitive behavioral therapy for tinnitus
Study: 33545015
Drug: Hexavalent rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexavalent rotavirus vaccine
Study: 35768167
Drug: SCPB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCPB with 10 mL of 0.5% ropivacaine
Study: 32423512
Drug: Dasotraline 6
Normalized name: Dasotraline
DrugBank: Dasotraline (DB12305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasotraline 6 mg/d
Study: 32423512
Drug: Dasotraline 4
Normalized name: Dasotraline
DrugBank: Dasotraline (DB12305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasotraline 4 mg/d
Study: 616083736
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (1.25 mg/0.05 mL)
Study: 616083736
Drug: Low-dose bevacizumab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bevacizumab (0.625 mg/0.025 mL) combined with low-dose triamcinolone (1 mg/0.025 mL)
Study: 34810296
Drug: TJP-008 (1-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJP-008 (1-day split dose)
Study: 34810296
Drug: TJP-008 (2-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJP-008 (2-day split dose)
Study: 34810296
Drug: 2L PEG
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2L PEG with ascorbate (2-day split dose)
Study: 33150732
Drug: Tailored habituation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored habituation protocol for MRI including gradual exposure to scanner noise, social stories booklet, positive incentive strategies, and Play Therapy support
Study: 32044802
Drug: Anterior suprascapular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior suprascapular block with 15 ml of ropivacaine 0.5% and epinephrine
Study: 32044802
Drug: Interscalene block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene block with 15 ml of ropivacaine 0.5% and epinephrine
Study: 33441355
Drug: SPA intervention
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPA intervention (10 weekly singing group sessions led by a music facilitator)
Study: 35926824
Drug: GSP301 nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSP301 nasal spray (olopatadine hydrochloride 665 μg and mometasone furoate 25 μg), 1 spray/each nostril twice daily for 14 days
Study: 35926824
Drug: GSP301 nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSP301 nasal spray
Study: 32011642
Drug: tPA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: tPA and DNase (4 mg tPA and 5 mg DNase)
Study: 32011642
Drug: tPA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: tPA and placebo (5 mL normal saline)
Study: 35883930
Drug: Specially designed
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specially designed physical therapy program
Study: 34397596
Drug: Sequential Feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Feeding (SF)
Study: 35819944
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin G (BPG)
Study: 34113095
Drug: Nemiralisib 750
Normalized name: Nemiralisib
DrugBank: Nemiralisib (DB16253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemiralisib 750 µg
Study: 34113095
Drug: Nemiralisib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemiralisib (all doses)
Study: 34325670
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 25mcg every 2 hours
Study: 34325670
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (titrated)
Study: 35220473
Drug: Melatonin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (4 mg, n = 419)
Study: 35639646
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg twice/day) and folic acid (400 μg /day)
Study: 35639646
Drug: Inofolic (inositol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inofolic (inositol + olic acid 200 μg twice/day)
Study: 34418398
Drug: Bexarotene (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexarotene (300 mg/m2 per day for 6 months)
Study: 35241690
Drug: Oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral verapamil
Study: 36452175
Drug: ENTF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENTF therapy (1–100 Hz, < 1 G), 40 min active treatment 5 days/week for 8 weeks; 3 treatments accompanied by 10 min of concurrent physical/occupational therapy.
Study: 36452175
Drug: Sham treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment, 40 min treatment 5 days/week for 8 weeks.
Study: 36452175
Drug: ENTF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENTF therapy
Study: 32106807
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose meropenem (3 g q8h)
Study: 32106807
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose meropenem (2 g q8h)
Study: 36364809
Drug: Personalized vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized vitamin D3 loading dose followed by daily 2000 IU
Study: 35667073
Drug: Intra-articular glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular glucocorticoid injection
Study: 32422597
Drug: Fitness tracker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitness tracker with daily step target for 6 weeks
Study: 33959920
Drug: Opioid pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid pain medication
Study: 33959920
Drug: Non-opioid pain
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opioid pain medication
Study: 32762505
Drug: Apple vinegar
Normalized name: apple cider vinegar
DrugBank: Apple cider vinegar (DB16596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple vinegar (AV) - 10 ml diluted in 200 ml drinking water with breakfast and dinner for 12 weeks
Study: 34503428
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids supplementation (oral, based on children's weight for three consecutive days)
Study: 34503428
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic treatment only
Study: 32131885
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of lipid-rich emollient
Study: 34708705
Drug: Paracetamol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol + Diclofenac
Study: 34281934
Drug: Direct swallowing
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct swallowing training + oral sensorimotor stimulation (DST+OSMS)
Study: 36410494
Drug: Nebulized TA
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized TA (500 mg tid)
Study: 36410494
Drug: IV TA
Normalized name: Liquid IV Tangerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV TA (500 mg tid)
Study: 35572853
Drug: LT4 treatment
Normalized name: LT4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LT4 treatment
Study: 35416437
Drug: Qingjin Yiqi
Normalized name: SILICON DIOXIDE 14 g in 100 g / .ALPHA.-TOCOPHEROL ACETATE 0.1 g in 100 g / SODIUM PYROPHOSPHATE 0.5 g in 100 g DENTAL PASTE, DENTIFRICE [Mastikis Qingjie Shine Mastic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingjin Yiqi granules (QJYQ) combined with standard rehabilitation treatments (SRTs)
Study: 32157434
Drug: Peritonsillar infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritonsillar infiltration of tramadol (2 mg/kg)
Study: 32157434
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 mL of peritonsillar saline)
Study: 34518459
Drug: Donepezil 23
Normalized name: donepezil 23 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 23 mg with/without dose titration (10 mg/day escalated to 23 mg)
Study: 34518459
Drug: No dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: No dose titration
Study: 34518459
Drug: Dose titration
Normalized name: Rebif Rebidose Titration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose titration
Study: 36716781
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (1 g)
Study: 32757324
Drug: Selective retina
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective retina therapy (SRT) with a wavelength of 527 nm
Study: 33180985
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment with vigabatrin
Study: 33180985
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with vigabatrin
Study: 34548243
Drug: Camelina sativa
Normalized name: CAMELINA SATIVA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camelina sativa oil (CSO) providing 10 g/d ALA
Study: 32419304
Drug: PF-06651600 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06651600 (200 mg once daily)
Study: 33234648
Drug: Dexmedetomidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.1 μg/kg/hour continuous infusion starting on the day of operation until 08:00 on postoperative day 1)
Study: 32665034
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline administered at the same rate as dexmedetomidine)
Study: 32404126
Drug: Solution Focused
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution Focused Brief Therapy (SFBT)
Study: 35361442
Drug: Placebo (olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (olive oil 1.6 g daily)
Study: 35101083
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 1 g intravenous bolus at the start and at the end of surgery
Study: 33543867
Drug: Sugammadex as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex as primary reversal agent
Study: 34267349
Drug: I-P-R-F vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-P-R-F vaccine
Study: 33009815
Drug: 6.8 mg
Normalized name: menthol 6.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.8 mg Neuropeptide Y (NPY)
Study: 33980168
Drug: Weekly befriending
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly befriending for 4 months from a trained volunteer
Study: 32140672
Drug: MD1003 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD1003 (300 mg/day)
Study: 33908635
Drug: Riluzole, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole, a benzothiazole sodium channel blocker, dosage and duration not specified.
Study: 32708292
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Dabigatran, Rivaroxaban, Apixaban, Warfarin)
Study: 32708292
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPIs) use
Study: 33720350
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate 200 mg once daily for 7 days
Study: 33720350
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg every 12 hours for 10 days
Study: 33225399
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (Lactobacillus casei Zhang, Lactobacillus plantarum P‐8, and Bifdobacterium animalis subsp. lactis V9) for 28 days
Study: 37787888
Drug: Basal-bolus insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal-bolus insulin regimen
Study: 32917410
Drug: Cemiplimab 3
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 3 mg/kg intravenously every 2 weeks for 48 weeks (monotherapy cohort)
Study: 32917410
Drug: Cemiplimab 3
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 3 mg/kg intravenously every 2 weeks for 48 weeks with hypofractionated radiation therapy (hfRT) during week 2 (combination cohort)
Study: 32996444
Drug: Antibiotic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic administration
Study: 35675940
Drug: Bupivacaine injection
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine injection after PRF ablation
Study: 35675940
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection after PRF ablation
Study: 35337692
Drug: Control (chemotherapy)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (chemotherapy)
Study: 38648814
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid
Study: 33991341
Drug: Risankizumab 150
Normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 150 mg (weeks 0, 4, and 16)
Study: 33991341
Drug: Fumaric acid
Normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumaric acid esters (FAEs) (30 mg daily up to 720 mg daily)
Study: 32086016
Drug: Control compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control compounds (existing shared latrines)
Study: 32086016
Drug: Intervention compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention compounds (hygienic emptying)
Study: 32985280
Drug: Probiotics (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (500 mg daily for 10 weeks)
Study: 32985280
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 10 weeks)
Study: 32926760
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment (RT delivered on the same day as or in between doses of ICT)
Study: 32926760
Drug: Nonconcurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonconcurrent treatment (RT not delivered on the same day as ICT)
Study: 33859685
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (0.4 mg/kg continuous infusion over 20 min)
Study: 33744981
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bevacizumab (IVB)
Study: 32432388
Drug: Lorecivivint 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorecivivint 0.07 mg
Study: 32432388
Drug: Lorecivivint 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorecivivint 0.03 mg
Study: 32432388
Drug: Lorecivivint 0.23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorecivivint 0.23 mg
Study: 33847018
Drug: L‐PRF
Normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐PRF
Study: 36386125
Drug: Xinbao pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinbao pill (XBP)
Study: 36386125
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug therapy combined with placebo